




**PORTEC-4a**



Trial setting: Stage I-II endometrial cancer - high-intermediate risk


Study Design: Randomised trial of molecular profile-based versus standard recommendations for adjuvant radiotherapy

Sponsor(s): LUMC; funding: Dutch Cancer Society


Planned No. of patients: 500



Current accrual: 46

Other important information: ANZGOG and NCRI UK preparing participation




➤ **Molecular integrated vs standard indications for adjuvant treatment:**





## Ongoing Trials – status update

PORTEC-4a



### Pilot phase (n=50) endpoints:

- Logistics of molecular analysis (< 2 wks)
- Patient acceptance
- **Current: 46 / 50 pts**



### PORTEC-4a study endpoints (n=500):

- Vaginal control and RFS
- Pelvic and distant recurrence and OS
- Quality of life and freedom from symptoms
- Costs and use of health care resources

➤ Satellite : Today, 2:30 h, State II Room